Net loss for the three-month period ended March 31, 2008, was $6.7 million or $0.52 per share as compared to a net loss of $3.7 million or $0.31 per share for the same period in 2007.
Research and development expenses, including contracted clinical activities, regulatory affairs and general research expenses increased 104% to $6.2 million for the three-month period ended March 31, 2008 from $3 million for the same period in 2007.